PulseSight Therapeutics is a clinical-stage biotech company developing disruptive, non-viral gene therapies dedicated to ophthalmology, with a current focus on age-related macular degeneration (AMD) including late-stage dry AMD/Geographic atrophy (GA) and wet AMD.
Latest news
January 26, 2026
PulseSight completes Phase 1 dosing of gene therapy candidate PST-611 in dry AMD and geographic atrophy
January 22, 2026
PulseSight Completes Enrollment in Gene Therapy Trial
January 22, 2026
A New Attack on Blindness: PulseSight Completes Key Safety Trial for Novel Dry AMD Gene Therapy